Infectious Disease
Conditions
Interventions
Amikacin treatment group:NA
Sponsors
Huashan Hospital affiliated to Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: (1) Patients of any gender and weight; over 18 years old; (2) Patients with bloodstream infections, infective endocarditis, pulmonary infections (including hospital-acquired pneumonia/ventilator-associated pneumonia), complex intra-abdominal infections, central nervous system infections, skin and soft tissue infections, bone and joint infections, etc. caused by multi-drug resistant Gram-negative bacillus infections that have been confirmed or suspected based on clinical symptoms, signs, laboratory tests and pathogenic microorganism tests; (3) Patients who need to apply amikacin for clinical reasons and are willing to undergo therapeutic drug concentration monitoring of amikacin; (4) Those who understand and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Those who have used nephrotoxic drugs (such as vancomycin, polymyxins, etc.) within 3 days before the start of amikacin treatment or are expected to use them during the study period; (2) Those whose course of amikacin treatment is less than 5 days (except for those undergoing hemodialysis and peritoneal dialysis); (3) Those who have participated in other clinical studies within the previous 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| plasma concentration; | — |
Countries
China
Contacts
Public ContactXiaofen Liu
Huashan Hospital affiliated to Fudan University
Outcome results
None listed